By Drug Target Review2025-12-09T08:30:01
Scientists have developed an experimental RNA-based drug, TY1, that repairs DNA, reduces scar tissue and could lead to new treatments for heart attacks and autoimmune diseases.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2023-05-18T10:39:07
Sponsored by BPS Bioscience
2023-07-11T16:13:06
Sponsored by Agilent
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2023-06-29T09:19:53
Sponsored by BMG Labtech GmbH
2023-02-23T14:02:18
Sponsored by bit.bio
2023-02-07T15:25:20
Sponsored by Bio-Techne
Site powered by Webvision Cloud